S

Stoke Therapeutics

Develops targeted gene upregulation therapies

Senior Scientist - Sterile Oligonucleotide Drug Product Development

Bioprocess & BiomanufacturingConfirmed live in the last 24 hours
Full-timeBedford, MA, USA

About the Job

Requirements

  • A PhD degree in Bio/Chemical Engineering, Pharmaceutical Sciences, Bio/Chemistry, or a related scientific field with 4 or more years of industry experience; alternatively, an MSc with 6 or more years of industry experience or a BSc with more than 10 years of industry experience.
  • At least one year of experience in oligonucleotide or mRNA sterile drug product development.
  • In-depth theoretical knowledge and hands-on experience with physicochemical and biophysical characterization methods and techniques, including differential scanning calorimetry, ultraviolet-visible spectroscopy, circular dichroism, high-performance liquid chromatography, liquid chromatography-mass spectrometry, particle counting and sizing, osmometry, and viscometry.
  • A demonstrated scientific track record in translatable oligonucleotide drug product process development through industry experience and/or external scientific publications and patents.
  • A strong background applying a scientific approach to experiment design and data analysis and interpretation.
  • Experience authoring reports, methods, and regulatory filings, and working knowledge of applicable and emerging FDA, EMA, ICH, and other regulatory requirements.
  • Familiarity with risk assessment tools such as Failure Mode and Effects Analysis, Failure Mode, Effects, and Criticality Analysis, and fishbone diagrams.
  • Familiarity with JMP, MasterControl, Veeva, and Prism.

Responsibilities

  • Develop oligonucleotide prototype formulations in-house, perform testing, and apply Design of Experiments where applicable to optimize and scale up processes from research and development to full-scale manufacturing at contract facilities.
  • Participate in selecting manufacturing equipment and oversee the process from prototype development to full-scale production of oligonucleotide drug products, both in-house and at contract manufacturing organizations when necessary.
  • Provide support to manufacturing operations as required.
  • Use problem-solving techniques to identify, assess, and mitigate potential manufacturing issues.
  • Review technical documents such as engineering studies, Master Batch Records, Executed Batch Records, Filter Validation Protocols, and other process validation protocols and manufacturing plans.
  • Travel to contract manufacturing organizations as required; the posting estimates approximately 10% travel.

Desired Qualifications

  • A good understanding of biopharma and oligonucleotide drug product and process development.
  • In-depth knowledge and hands-on experience with oligonucleotide delivery, including intrathecal, ocular, and intravenous delivery routes.
  • Experience with ASO-peptide, ASO-antibody, or ASO-small molecule conjugate formulation and process development, including conjugation strategies, purification, and stability characterization of these complex modalities.
  • Familiarity with bioconjugation chemistry and analytical methods used to characterize ASO-conjugate constructs, such as conjugate-specific high-performance liquid chromatography, liquid chromatography-mass spectrometry, and peptide mapping.
  • Understanding of the unique formulation and stability challenges associated with ASO-conjugated drug products, including aggregation, conjugate stability, and immunogenicity considerations for ASO-antibody constructs.
  • Experience with high-throughput screening and/or analytical characterization techniques for oligonucleotide drug products, including ultraviolet-visible spectroscopy, circular dichroism, static and dynamic light scattering, particle characterization, Fourier-transform infrared spectroscopy, infrared spectroscopy, differential scanning calorimetry, and chromatography.
  • Ability to independently lead, design, conduct, and analyze experiments.

About the Company

Stoke Therapeutics

Develops targeted gene upregulation therapies

Stoke Therapeutics develops therapies for severe genetic diseases caused by loss of function in a single gene, aiming to restore missing proteins by upregulating protein expression. Its main product approach relies on the TANGO (Targeted Augmentation of Nuclear Gene Output) platform, which delivers precise, durable, and controllable upregulation of gene expression across a range of tissues to re-create the missing protein. Compared with many biotech firms, Stoke centers on upregulating endogenous gene output rather than replacing genes or adding new ones, and focuses on disease-modifying treatments for rare disorders with unmet medical needs. Revenue comes from partnerships, licensing agreements, and, ultimately, commercialization of its therapies. The company’s goal is to provide targeted, durable treatments that address the underlying genetic deficiency and improve outcomes for patients with limited options.

Company size
201-500
Company stage
IPO
Headquarters
Bedford, TX
Founded
2014

Recently Posted Jobs

Explore more opportunities at Stoke Therapeutics

See more jobs